AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?

Epidermal growth factor receptor (EGFR) is highly expressed in triple-negative breast cancer (TNBC), and elevated levels correlate with poor prognosis. In analogy with the paradigm of oncogene addiction, blocking EGFR in TNBC was expected to have clinical efficacy – but this has not been the case. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Heideman, Marinus R, Hynes, Nancy E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978757/
https://www.ncbi.nlm.nih.gov/pubmed/24172042
http://dx.doi.org/10.1186/bcr3564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978757/
https://www.ncbi.nlm.nih.gov/pubmed/24172042
http://dx.doi.org/10.1186/bcr3564

Ejemplares similares